Prostaglandin D2metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Mast cells (MCs) participate in diseases such as systemic mastocytosis (SM) and allergic conditions. Less well understood is the role of MCs in non-allergic inflammatory disorders like rheumatoid arthritis (RA). Studying definitive roles for MCs in human diseases has been hampered by the lack of a well-accepted biomarker for monitoring in vivo MC activation. This study aimed to investigate the utility of urinary tetranor PGDM (T-PGDM) as a biomarker of in vivo MC activation in patients with SM, and apply this biomarker to assess MC involvement in relation to RA disease activity. A prospective, cross-sectional cohort study was conducted to measure a major urinary metabolite of prostaglandin D2, T-PGDM. Urine samples were collected from patients with RA (n = 60), SM (n = 17) and healthy normal controls (n = 16) and T-PGDM excretion was determined by enzyme immunoassay as nanograms per milligram of urinary creatinine (ng/mg Cr). Mean urinary T-PGDM excretion was significantly higher (p < 0.01) in patients with SM compared to controls (37.2 vs. 11.5 ng/mg Cr) with 65% of SM patients showing elevated levels. One third of patients with RA had elevated T-PGDM excretion, and the mean level in the RA group (20.0 ng/mg Cr) was significantly higher than controls (p < 0.01). Medications inhibiting cyclooxygenase reduced T-PGDM excretion. Urinary T-PGDM excretion appears promising as a biomarker of in vivo MC activity and elevated levels in 33% of patients with RA provides evidence of MC activation in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Galli, S. J., & Tsai, M. (2010) · European Journal of Immunology · doi:10.1002/eji.201040559 · Cited by 403
Mast cell activation syndrome: A newly recognized disorder with systemic clinical manifestations
Hamilton, M. J., Hornick, J. L., Akin, C., Castells, M. C., & Greenberger, N. J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.037 · Cited by 132 · cited 1×
“There is a growing body of evidence to suggest MCs play a far greater role in human disease than is currently understood [16].”
BackgroundIncreased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis
Ono, E., Taniguchi, M., Mita, H., Fukutomi, Y., Higashi, N., Miyazaki, E., Kumamoto, T., & Akiyama, K. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03104.x · Cited by 118 · cited 2×
“The F-ring PGD2 metabolite, 9a,11bPGF2 and D-ring T-PGDM have been found to increase during an exacerbation of anaphylaxis and aspirin-induced asthma, returning to baseline during resolution [9, 11, 14, 15].”
BackgroundAwad, J. A., Morrow, J. D., & Roberts, L. J. (1994) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(94)90371-9 · Cited by 66
Ravi, A., Butterfield, J., & Weiler, C. R. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.06.011 · Cited by 63
Valent, P., Horny, H.-P., Triggiani, M., & Arock, M. (2011) · International Archives of Allergy and Immunology · doi:10.1159/000323763 · Cited by 50 · cited 2×
“Existing biomarkers, histamine and tryptase have been shown to be elevated in this disease, reflecting increased MC load and activity [6].”
Background
Cited by
Mast cell activation syndromes: Collegium Internationale Allergologicum update 2022
Valent, P., Hartmann, K., Bonadonna, P., Niedoszytko, M., Triggiani, M., Arock, M., & Brockow, K. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000524532 · Cited by 55
Mast cell mediators of significance in clinical practice in mastocytosis
Butterfield, J. H., Ravi, A., & Pongdee, T. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.011 · Cited by 48
Butterfield, J., & Weiler, C. R. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.02.021 · Cited by 41
Butterfield, J. H. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.03.008 · Cited by 27
Metadata
- Authors
- Cho, C., Nguyen, A., Bryant, K. J., O'Neill, S. G., & McNeil, H. P.
- Venue
- Immunity, Inflammation and Disease
- Publisher
- Wiley
- Published
- 2015-11-25
- Volume
- 4
- Issue
- 1
- Pages
- 64-69
- ISSN
- 2050-4527 (ISSN-L)
- OpenAlex
- W2294233595
- Cited by
- 30
- References
- 6
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostaglandin D2metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/iid3.94
- The paper
- Cho, C., Nguyen, A., Bryant, K. J., O'Neill, S. G., & McNeil, H. P. (2016). Prostaglandin D2metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.94
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.